These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

499 related articles for article (PubMed ID: 27115525)

  • 21. Comparative efficacy and safety of mineralocorticoid receptor antagonists in heart failure: a network meta-analysis of randomized controlled trials.
    Yang P; Shen W; Chen X; Zhu D; Xu X; Wu T; Xu G; Wu Q
    Heart Fail Rev; 2019 Sep; 24(5):637-646. PubMed ID: 31030322
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of Finerenone, a Novel Nonsteroidal Mineralocorticoid Receptor Antagonist, on Cardiovascular Disease, Chronic Kidney Disease, and Blood Pressure.
    Ravid JD; Laffin LJ
    Curr Cardiol Rep; 2022 Oct; 24(10):1251-1259. PubMed ID: 35925515
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Finerenone in diabetic kidney disease: A systematic review and critical appraisal.
    Singh AK; Singh A; Singh R; Misra A
    Diabetes Metab Syndr; 2022 Oct; 16(10):102638. PubMed ID: 36223666
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Finerenone : third-generation mineralocorticoid receptor antagonist for the treatment of heart failure and diabetic kidney disease.
    Liu LC; Schutte E; Gansevoort RT; van der Meer P; Voors AA
    Expert Opin Investig Drugs; 2015; 24(8):1123-35. PubMed ID: 26095025
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Finerenone Impedes Aldosterone-dependent Nuclear Import of the Mineralocorticoid Receptor and Prevents Genomic Recruitment of Steroid Receptor Coactivator-1.
    Amazit L; Le Billan F; Kolkhof P; Lamribet K; Viengchareun S; Fay MR; Khan JA; Hillisch A; Lombès M; Rafestin-Oblin ME; Fagart J
    J Biol Chem; 2015 Sep; 290(36):21876-89. PubMed ID: 26203193
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mineralocorticoid receptor antagonism improves diastolic dysfunction in chronic kidney disease in mice.
    Bonnard B; Pieronne-Deperrois M; Djerada Z; Elmoghrabi S; Kolkhof P; Ouvrard-Pascaud A; Mulder P; Jaisser F; Messaoudi S
    J Mol Cell Cardiol; 2018 Aug; 121():124-133. PubMed ID: 29981797
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The Nonsteroidal Mineralocorticoid-Receptor-Antagonist Finerenone in Cardiorenal Medicine: A State-of-the-Art Review of the Literature.
    Georgianos PI; Agarwal R
    Am J Hypertens; 2023 Feb; 36(3):135-143. PubMed ID: 36331811
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Mineralocorticoid receptor antagonists and kidney diseases: pathophysiological basis.
    Barrera-Chimal J; Girerd S; Jaisser F
    Kidney Int; 2019 Aug; 96(2):302-319. PubMed ID: 31133455
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Nonsteroidal Mineralocorticoid Receptor Antagonist Finerenone Protects Against Acute Kidney Injury-Mediated Chronic Kidney Disease: Role of Oxidative Stress.
    Lattenist L; Lechner SM; Messaoudi S; Le Mercier A; El Moghrabi S; Prince S; Bobadilla NA; Kolkhof P; Jaisser F; Barrera-Chimal J
    Hypertension; 2017 May; 69(5):870-878. PubMed ID: 28320854
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Direct Blood Pressure-Independent Anti-Fibrotic Effects by the Selective Nonsteroidal Mineralocorticoid Receptor Antagonist Finerenone in Progressive Models of Kidney Fibrosis.
    Droebner K; Pavkovic M; Grundmann M; Hartmann E; Goea L; Nordlohne J; Klar J; Eitner F; Kolkhof P
    Am J Nephrol; 2021; 52(7):588-601. PubMed ID: 34515038
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Preclinical pharmacology of AZD9977: A novel mineralocorticoid receptor modulator separating organ protection from effects on electrolyte excretion.
    Bamberg K; Johansson U; Edman K; William-Olsson L; Myhre S; Gunnarsson A; Geschwindner S; Aagaard A; Björnson Granqvist A; Jaisser F; Huang Y; Granberg KL; Jansson-Löfmark R; Hartleib-Geschwindner J
    PLoS One; 2018; 13(2):e0193380. PubMed ID: 29474466
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Design and Baseline Characteristics of the Finerenone in Reducing Kidney Failure and Disease Progression in Diabetic Kidney Disease Trial.
    Bakris GL; Agarwal R; Anker SD; Pitt B; Ruilope LM; Nowack C; Kolkhof P; Ferreira AC; Schloemer P; Filippatos G; ;
    Am J Nephrol; 2019; 50(5):333-344. PubMed ID: 31655812
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Finerenone, a novel selective nonsteroidal mineralocorticoid receptor antagonist protects from rat cardiorenal injury.
    Kolkhof P; Delbeck M; Kretschmer A; Steinke W; Hartmann E; Bärfacker L; Eitner F; Albrecht-Küpper B; Schäfer S
    J Cardiovasc Pharmacol; 2014 Jul; 64(1):69-78. PubMed ID: 24621652
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The Ascent of Mineralocorticoid Receptor Antagonists in Diabetic Nephropathy.
    Goenka L; Padmanaban R; George M
    Curr Clin Pharmacol; 2019; 14(2):78-83. PubMed ID: 30444201
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Mineralocorticoid Receptor Antagonists-Use in Chronic Kidney Disease.
    Baran W; Krzemińska J; Szlagor M; Wronka M; Młynarska E; Franczyk B; Rysz J
    Int J Mol Sci; 2021 Sep; 22(18):. PubMed ID: 34576158
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Nonsteroidal mineralocorticoid receptor antagonism for cardiovascular and renal disorders - New perspectives for combination therapy.
    Kolkhof P; Joseph A; Kintscher U
    Pharmacol Res; 2021 Oct; 172():105859. PubMed ID: 34461222
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Non-steroidal mineralocorticoid receptor antagonism for the treatment of cardiovascular and renal disease.
    Bramlage P; Swift SL; Thoenes M; Minguet J; Ferrero C; Schmieder RE
    Eur J Heart Fail; 2016 Jan; 18(1):28-37. PubMed ID: 26634965
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Finerenone - are we there yet with a non-steroidal mineralocorticoid receptor antagonist for the treatment of diabetic chronic kidney disease?
    Doggrell SA
    Expert Opin Pharmacother; 2021 Jul; 22(10):1253-1256. PubMed ID: 33764251
    [No Abstract]   [Full Text] [Related]  

  • 39. Adverse Effects of Mineralocorticoid Receptor Antagonist Administration.
    Kallistratos MS; Pittaras A; Theodoulidis I; Grassos C; Poulimenos LE; Manolis AJ
    Curr Pharm Des; 2018; 24(46):5537-5541. PubMed ID: 30799782
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Nonsteroidal Mineralocorticoid Receptor Antagonism by Finerenone-Translational Aspects and Clinical Perspectives across Multiple Organ Systems.
    Kolkhof P; Lawatscheck R; Filippatos G; Bakris GL
    Int J Mol Sci; 2022 Aug; 23(16):. PubMed ID: 36012508
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.